What is Boston Scientific?
Interventional medical devices company with $20.074B of 2025 revenue and enterprise healthcare scale.
- Category
- Interventional medical devices
- Headquarters
- Marlborough, MA
- Founded
- 1979
- Employees
- 59,000+
- Total funding
- Public company; no VC funding
- Status
- NYSE: BSX; ~$160B market cap
What is Boston Scientific?
Boston Scientific is a public interventional medical devices company headquartered in Marlborough, MA. It reported $20.074B of 2025 revenue and operates at global enterprise scale.
Boston Scientific operates in interventional medical devices with a portfolio spanning MedSurg and Cardiovascular. The company reported $20.074B of 2025 revenue, employs about 59,000+, and trades as NYSE: BSX. Its customer base is large, regulated, and relationship-driven, with purchasing decisions shaped by clinical outcomes, compliance, reimbursement, operating leverage, and long-term supply reliability.
The company's scale comes from durable demand in healthcare, recurring consumables or services, installed bases, payer or provider relationships, and disciplined capital allocation. Unlike early-stage software companies, Boston Scientific is evaluated through revenue growth, margins, cash flow, reimbursement exposure, procedure or prescription volume, quality, and regulatory execution.
For sellers, Boston Scientific is not a single buying center. The practical map includes procurement, finance, clinical, IT, security, compliance, operations, supply chain, commercial teams, and business-unit executives. Strong pitches connect directly to patient outcomes, cost-to-serve, risk reduction, revenue capture, uptime, or measurable productivity.
What does Boston Scientific offer?
Boston Scientific offers healthcare products and services across MedSurg and Cardiovascular.
- Cardiology devices· Cardiovascular
- Electrophysiology· Cardiovascular
- Endoscopy· MedSurg
- Urology and pelvic health· MedSurg
- Neuromodulation· Neuroscience
- Peripheral interventions· Vascular
- Structural heart· Cardiovascular
How does Boston Scientific make money?
Boston Scientific sells physician-preference devices, implants, single-use products, capital-adjacent systems, service, and clinical support into hospitals, outpatient sites, and specialty physician groups.
Boston Scientific sells physician-preference devices, implants, single-use products, capital-adjacent systems, service, and clinical support into hospitals, outpatient sites, and specialty physician groups. In 2025, that model produced $20.074B of revenue, showing the scale of the installed base, service footprint, payer/provider contracts, or distribution volume behind the business.
Pricing is negotiated by device category, procedure, account, GPO, reimbursement, service requirements, and geography rather than public tiers; growth is driven by procedure volume, product launches, indications, and M&A. That makes the relevant "pricing tier" for sellers an enterprise contracting motion: account segmentation, compliance review, value analysis, legal terms, security review, reimbursement impact, and multi-year renewal economics.
Growth is driven by a mix of market expansion, procedure or prescription volume, product launches, acquisitions, geographic reach, contract renewals, operational efficiency, and technology adoption. Vendors should expect rigorous procurement, documented ROI, data-security requirements, and evidence that the product can work inside regulated healthcare operations.
Who leads Boston Scientific?
Boston Scientific is led by Michael F. Mahoney, with finance, operations, clinical, technology, and business-unit leaders shaping major enterprise decisions.
- Michael F. MahoneyChairman and Chief Executive OfficerCEO since 2012Leads Boston Scientific's innovation and acquisition strategy.
- Jonathan R. MonsonExecutive Vice President and Chief Financial OfficerCFO in 2026Finance leader listed on Boston Scientific's leadership page.
- Joseph M. FitzgeraldExecutive Vice President and Group President, CardiovascularSenior executive leadershipRuns the largest device growth platform.
- Arthur C. ButcherExecutive Vice President and Group President, MedSurg and Asia PacificSenior executive leadershipLeads MedSurg and international growth priorities.
How do you contact Boston Scientific's leadership?
Boston Scientific publishes investor-relations, media, supplier, customer, and compliance channels, but it does not publish verified personal executive emails for the listed leaders. Use the public investor-relations route (investor_relations@bsci.com) or official contact forms rather than guessed personal addresses.
investor_relations@bsci.com is a public investor/contact route; personal executive email format not verified- Joseph M. FitzgeraldExecutive Vice President and Group President, Cardiovascularinvestor_relations@bsci.com
How much funding has Boston Scientific raised?
Boston Scientific is a mature public company, not a venture-backed startup. It trades as NYSE: BSX, had an approximate ~$160B market capitalization in June 2026, and funds growth through operating cash flow, debt markets, public equity access, and acquisition capacity.
Boston Scientific's capital history is a public-company story rather than a disclosed venture-round history. The relevant milestones are founding in 1979, public-market access, acquisitions, debt capacity, dividends or buybacks where applicable, and reinvestment in regulated healthcare capabilities.
The company reported $20.074B of 2025 revenue and operates with the financing tools expected of a large public healthcare company. Capital is directed toward product development, clinical evidence, facilities, inventory, technology, acquisitions, compliance, reimbursement capabilities, and shareholder returns depending on the business model.
Seller signal: Boston Scientific has meaningful buying power, but budget access is tied to risk, ROI, compliance, and executive sponsorship. Vendors should map proposals to cost reduction, growth, care quality, automation, supply resilience, cybersecurity, data quality, or measurable operating improvement.
How did Boston Scientific get here?
Boston Scientific grew through founding, public-market scale, product expansion, acquisitions, and healthcare-market execution.
- 1979Company foundedBoston Scientific begins as a less-invasive medical-device company.
- 1992IPOBoston Scientific becomes publicly traded.
- 2006Guidant acquisitionThe company expands cardiovascular scale.
- 2019BTG acquiredBoston Scientific expands peripheral intervention and oncology assets.
- 2025$20.074B net salesThe company reports nearly 20% reported growth.
- 2026Penumbra transaction announcedBoston Scientific announces a major thrombectomy and vascular expansion deal.
Who are Boston Scientific's competitors?
Boston Scientific competes with companies that overlap in customers, budgets, clinical categories, distribution channels, or healthcare services.
- MedtronicBroader medtech competitor across cardiovascular, neuro, surgical, and diabetes devices.
- AbbottCompetes in electrophysiology, structural heart, vascular, and neuromodulation.
- Johnson & Johnson MedTechSurgery and electrophysiology competitor with broad hospital relationships.
- StrykerHospital-medtech competitor in neurovascular and procedural budgets.
- Edwards LifesciencesStructural heart competitor focused on transcatheter therapies.
Boston Scientific — frequently asked questions
